Dong H, Lee C M, Ng K W, Wong T M
Department of Biophysics, School of Basic Medical Sciences, Shanghai Medical University, P.R.C.
Arch Int Pharmacodyn Ther. 1995 Mar-Apr;329(2):245-54.
The cardiovascular effects of intracerebroventricular (i.c.v.) injections of low doses of CPU-23, a substituted tetrahydroisoquinoline, were investigated and compared with those of nifedipine in pentobarbital-anaesthetized Sprague-Dawley rats. CPU-23, in doses of 0.2 to 0.5 mg/kg (i.c.v.), which did not elicit any significant cardiovascular responses when injected intravenously, caused a clear-cut and long-lasting decrease of mean arterial pressure (MAP) and heart rate (HR) in a dose-dependent manner. The effects of CPU-23, in a dose of 0.05 mg/kg, were similar to those of nifedipine, a prototype L-type calcium antagonist. The hypotensive effects of CPU-23 were significantly attenuated by bilateral cervical vagotomy. The results strongly suggest that a central component may be involved in the cardiovascular effects of CPU-23 and that dihydropyridine receptor sites in the brain may be involved in the central control of cardiovascular functions.
研究了脑室内（i.c.v.）注射低剂量CPU-23（一种取代四氢异喹啉）对心血管的影响，并在戊巴比妥麻醉的Sprague-Dawley大鼠中将其与硝苯地平的影响进行了比较。静脉注射时不会引起任何显著心血管反应的剂量为0.2至0.5毫克/千克（i.c.v.）的CPU-23，以剂量依赖性方式导致平均动脉压（MAP）和心率（HR）明显且持久地降低。剂量为0.05毫克/千克的CPU-23的作用与原型L型钙拮抗剂硝苯地平的作用相似。双侧颈迷走神经切断术可显著减弱CPU-23的降压作用。结果强烈表明，中枢成分可能参与了CPU-23的心血管作用，并且脑中的二氢吡啶受体位点可能参与了心血管功能的中枢控制。
